{"metadata": {"source": "erowid", "title": "Erowid Buprenorphine (Temgesic, Subutex) Vault", "description": "Information about Buprenorphine (Temgesic, Subutex) including uses, images, and links to other resources.", "language": "No language found.", "url": "https://www.erowid.org/pharms/buprenorphine/buprenorphine.shtml", "drug": "Buprenorphine", "cid": 644073, "substance": "buprenorphine", "category": "PHARMS", "erowid_column": "MainPage", "char_count": 6146, "word_count": 850, "doc_id": "doc_107", "num_chunks": 8, "chunk_id": "107::chunk_6", "document_index": 107, "latency_s": 0.5684546000120463, "prompt_toks": 2109, "completion_toks": 64, "relevance_score": 7.1832605e-06}, "content": "Drug: Buprenorphine | cid: 644073\nSource: erowid | Source description: Information about Buprenorphine (Temgesic, Subutex) including uses, images, and links to other resources.\nErowid name: buprenorphine\nCategory: PHARMS\nField: MainPage\n\n                    Text: \n                    ADDICTION & TREATMENT #\n\nFDA approves first buprenorphine implant [...] - FDA News Release, May 26 2016\n\nBuprenorphine Proves Effective Treatment for Heroin Addiction - NIDA Notes\n\nBuprenorphine Drug Detox - Information and list of Physicians and Treatment Centers\n\nSo You Thought You Could Get Off Suboxone? - The Fix.com, Sep 4, 2014\n\nMEDIA COVERAGE #\n\nThe New York Times is dead wrong about drug addiction - Dec 22, 2013, salon.com\n\nAddiction Treatment With a Dark Side - Nov 16, 2013, NYTimes\n\nPharma Gamesmanship in the Booming Business of Addiction Therapeutics: the Case of Suboxone - Mar 2013, efcannon\n\nCongress increases doctors' ability to prescribe buprenorphine for opiod addiction, Dec 2006, PRNewswire\n\nCity moves to expand drug treatment access, Oct 4 2006, baltimoresun.com\n\nPer-doctor prescription caps limit treatment of addicts, Jun 12 2006, Post-Gazette.com\n\nNew drug treats the new face of addiction - USA Today, Jan 24 2006\n\n\n                    Context: \n                    This chunk provides information on addiction treatment and media coverage related to buprenorphine, highlighting FDA approvals, effectiveness for heroin addiction, detox resources, treatment access, and notable news articles from 2006 to 2016, making it relevant for understanding buprenorphine’s role in therapy and public discourse.\n                "}
{"metadata": {"source": "psychonaut", "title": "Oxycodone - PsychonautWiki", "description": "Oxycodone (also known under brand names including Roxicodone, OxyContin, Percocet, Oxecta, OxyIR, Endone, Oxynorm, and OxyNEO) is a semi-synthetic opioid synthesized from poppy-derived thebaine. It is a narcotic analgesic within the morphinan chemical class and is generally indicated for relief of moderate to severe pain. It was developed in 1916 in Germany[2][3] as one of several new semi-synthetic opioids in an attempt to improve on the existing opioids.[4]", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Oxycodone", "drug": "Oxycodone", "cid": 5284603, "char_count": 20642, "word_count": 2894, "doc_id": "doc_88", "num_chunks": 28, "chunk_id": "88::chunk_25", "document_index": 88, "latency_s": 0.5753269999986514, "prompt_toks": 5623, "completion_toks": 46, "relevance_score": 5.0540657e-06}, "content": "Drug: Oxycodone | cid: 5284603\nSource: psychonaut | Source description: Oxycodone (also known under brand names including Roxicodone, OxyContin, Percocet, Oxecta, OxyIR, Endone, Oxynorm, and OxyNEO) is a semi-synthetic opioid synthesized from poppy-derived thebaine. It is a narcotic analgesic within the morphinan chemical class and is generally indicated for relief of moderate to severe pain. It was developed in 1916 in Germany[2][3] as one of several new semi-synthetic opioids in an attempt to improve on the existing opioids.[4]\n\n                    Text: \n                    ↑ Why Heroin Relapse Often Ends In Death - Lauren F Friedman (Business Insider) | http://www.businessinsider.com.au/philip-seymour-hoffman-overdose-2014-2\n\n↑ Siegel, S., Hinson, R. E., Krank, M. D., McCully, J. (23 April 1982). \"Heroin \"Overdose\" Death: Contribution of Drug-Associated Environmental Cues\". Science. 216 (4544): 436–437. doi:10.1126/science.7200260. ISSN 0036-8075.\n\n↑ 10.0 10.1 Ershad, M., Cruz, M. D., Mostafa, A., Mckeever, R., Vearrier, D., Greenberg, M. I. (March 2020). \"Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance\". Journal of Addiction Medicine. 14 (2): 172–174. doi:10.1097/ADM.0000000000000535. ISSN 1932-0620.\n\n↑ VI.8a Convention for limiting the Manufacture and regulating the Distribution of Narcotic Drugs. Geneva, 13 July 1931 | https://treaties.un.org/doc/Treaties/1931/07/19310713%2006-44%20AM/Ch_VI_8_ap.pdf\n\n\n                    Context: \n                    This excerpt provides references and citations related to the dangers of heroin overdose, environmental factors influencing overdose risk, and international drug treaties, highlighting legal regulations and the complexities of opioid-related fatalities discussed in the full document on oxycodone.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Naltrexone (ReVia, Vivitrol) Vault", "description": "Information about Naltrexone (ReVia) including uses, images, dosage, effects, legal status, and links to other resources.", "language": "No language found.", "url": "https://www.erowid.org/pharms/naltrexone/naltrexone.shtml", "drug": "Naltrexone", "cid": 5360515, "substance": "naltrexone", "category": "PHARMS", "erowid_column": "MainPage", "char_count": 5417, "word_count": 753, "doc_id": "doc_207", "num_chunks": 7, "chunk_id": "207::chunk_5", "document_index": 207, "latency_s": 0.7839301000058185, "prompt_toks": 1843, "completion_toks": 96, "relevance_score": 4.710909e-06}, "content": "Drug: Naltrexone | cid: 5360515\nSource: erowid | Source description: Information about Naltrexone (ReVia) including uses, images, dosage, effects, legal status, and links to other resources.\nErowid name: naltrexone\nCategory: PHARMS\nField: MainPage\n\n                    Text: \n                    Injectable extended-release naltrexone for opioid dependence [...], 2016\n\nObviation of opioid withdrawal syndrome by concomitant administration of naltrexone [...], 2006\n\nEvidence about the use of naltrexone and [...] ways of using it in the treatment of alcoholism, 2001\n\nNaltrexone treatment of hallucinogen persisting perception disorder, 1997\n\n» » » MORE » » »\n\nEXPERIENCES #\n\nReal Buzzkill Tech, by Gleetnorx\n\nPrecipitated Withdrawal, by The Weez\n\n» » » MORE » » »\n\nSubmit a Report to our Experience Vaults\n\nOFF-SITE RESOURCES\n\nSECONDARY RESOURCES #\n\nNaltrexone - Australian Drug Foundation\n\nMedLine Plus: Naltrexone\n\nLow Dose Naltrexone.org\n\nWhat is Naltrexone? - DrugWise UK\n\nNaltrexone Guide for Users - Mental Health and Drug & Alcohol Office, NSW\n\nARTICLES & WRITINGS #\n\nNaltrexone: An Antagonist Therapy for Heroin Addiction, NIDA Treatment Workgroup (1999)\n\nMEDIA COVERAGE #\n\n\n                    Context: \n                    This excerpt from the webpage provides a curated list of recent research articles, experiences, and external resources related to naltrexone, highlighting its clinical studies, patient reports, and informational links. It is part of the broader \"Pharms\" section, which details various pharmaceuticals and their uses, emphasizing naltrexone's role in addiction treatment and associated research. This collection enhances understanding of naltrexone's medical applications and user experiences while connecting users to further information sources.\n                "}
